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Abstract
Background: Chondroblastoma is a benign cartilaginous tumour of bone that predominantly affects the
epiphysis of long bones in young males. No recurrent chromosomal re-arrangements have so far been observed.
Methods: We identified an index case with a balanced translocation by Combined Binary Ratio-Fluorescent in situ
Hybridisation (COBRA-FISH) karyotyping followed by breakpoint FISH mapping and array-Comparative Genomic
Hybridisation (aCGH). Candidate region re-arrangement and candidate gene expression were subsequently
investigated by interphase FISH and immunohistochemistry in another 14 cases.
Results: A balanced t(5;17)(p15;q22-23) was identified. In the index case, interphase FISH showed that the
translocation was present only in mononucleated cells and was absent in the characteristic multinucleated giant
cells. The t(5;17) translocation was not observed in the other cases studied. The breakpoint in 5p15 occurred
close to the steroid reductase 5α1 (SRD5A1) gene. Expression of the protein was found in all cases tested. Similar
expression was found for the sex steroid signalling-related molecules oestrogen receptor alpha and aromatase,
while androgen receptors were only found in isolated cells in a few cases. The breakpoint in 17q22-23 was
upstream of the carbonic anhydrase × (CA10) gene region and possibly involved gene-regulatory elements, which
was indicated by the lack of CA10 protein expression in the index case. All other cases showed variable levels of
CA10 expression, with low expression in three cases.
Conclusion: We report a novel t(5;17)(p15;q22-23) translocation in chondroblastoma without involvement of
any of the two chromosomal regions in other cases studied. Our results indicate that the characteristic
multinucleated giant cells in chondroblastoma do not have the same clonal origin as the mononuclear population,
as they do not harbour the same translocation. We therefore hypothesise that they might be either reactive or
originate from a distinct neoplastic clone, although the occurrence of two distinct clones is unlikely. Impairment
of the CA10 gene might be pathogenetically relevant, as low expression was found in four cases. Diffuse expression
of SRD5A1 and sex steroid signalling-related molecules confirms their role in neoplastic chondrogenesis.
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Chondroblastoma is a benign bone tumour that mainly
affects the epiphysis of long bones in young males (male
to female ratio 1.5:1; peak of occurrence: second decade)
[1-3]. Its nomenclature stems from the presence of cells
resembling immature cartilage cells (chondroblasts) set
within a distinctive and heterogeneous extracellular
matrix [1-3]. The latter is mainly a 'chondroid' extracellu-
lar matrix; however, osteoid and fibrous matrix deposits
are often observed [1-3]. The lack of a clear-cut, identifia-
ble cartilage extracellular matrix has caused uncertainty
on the nature of this tumour [4]. However, recent litera-
ture has shown that chondroblastomas share a homoge-
nous expression profile with other cartilage-forming
tumours, confirming the cartilaginous nature of this
lesion [5,6]. The distinct clinical features of epiphyseal
occurrence in pre-pubertal patients suggest a role for
growth plate signalling in the pathogenesis of this lesion.
Accordingly, we have previously shown IHH/PTHLH and
FGF signalling to be active in chondroblastoma [7]. Sex
steroids are also likely involved in this process; their role
in the pubertal growth spurt and subsequent epiphyseal
fusion is well-established [8]. Furthermore, both in vivo
expression of oestrogen receptors as well as in vitro oestro-
gen/induced proliferation-survival have been previously
shown in cartilaginous tumours [9,10]. However, clear
understanding of the genetic mechanism driving the
pathogenesis of chondroblastoma is lacking. No recurrent
chromosomal rearrangements have yet been described
(Table 1) [11-15]. Herein, we identified an index case with
a balanced translocation t(5;17) with breakpoints map-
ping close to the CA10 and SRD5A1 genes and further
investigated the involvement of candidate regions/genes
in 14 other chondroblastoma cases.
Methods
Patients
Paraffin embedded, formalin fixed and, if available, snap
frozen tumour samples from fifteen patients were col-
lected. The clinical-demographic details of patients were
previously published [5,7]. All samples were handled in a
coded fashion, and all procedures were performed accord-
ing to the ethical guidelines, "Code for Proper Secondary
Use of Human Tissue in the Netherlands" (Dutch Federa-
tion of Medical Scientific Societies).
Multicolour fluorescence in situ hybridisation (COBRA-
FISH)
For one case (chondroblastoma 13; CB 13), primary cells
were isolated from the tumour by using mechanical and
enzymatic dissociation procedures. Culture and harvest
conditions were performed as described previously [16].
The 43-color FISH staining of every chromosome arm in a
different colour combination, digital imaging and analy-
sis were performed as previously described [16]. Hybridi-
sations with individual whole chromosome painting
probes labelled with single fluorochromes were used to
confirm the detected re-arrangements. Chromosomal
breakpoints were assigned by using inverted images coun-
terstained with 4',6-diamidino-2-phenylindole (DAPI;
Downers Grove, IL) together with the information derived
from the short- and long-arm-specific hybridisation from
the COBRA-FISH and FISH mapping data. Karyotypes
were described according to ISCN 2005.
FISH Mapping
Nick translation labelled, large genomic insert clones
from the library used for the array-CGH [17] with about 1
Mb spacing were used to map the translocation break-
Table 1: Conventional cytogenetic findings of chondroblastomas available in the literature. Involvement of chromosome 5 and 17 is 
shown in bold.
Chromosome changes in chondroblastoma Reference
46, XX, t(1;1;5;17;22)(q42;p32;p13;q12;q21;q12~13) [9]
46, XY, add(11)(p15)/47, XY, +mar [10]
46, XY, inv(18)(q11q21) [10]
47, XY, +der(5)t(2;5)(q11;q11), der(21)t(8;21)(q21q13) 45, XY, del(2)(p23), del(3)(q23q27), dup(8)(q12aq21.3), del(11)(q14q23), 
13, add(17)(q25)2
[10]
45, XY, del(2)(p23), del(3)(q23q27), dup(8)(q12aq21.3), del(11)(q14q23), -13, add(17)(q25)x2 [11]
47, XY, +5, t(5;5)(p10;q10) [11]
46, XY, r(4) [13]
41-46, XY, -5, -7, -8, 9qh+c [cp13] [12]
46, X, -Y, del(2)(q33~35), +7 [cp9] [12]
46, XY, del(18)(q21) [3]/46XY [8] [12]
46XY, t(2;22;5)(q35;q13;q31), inv9(p13q21)c[9]/46, XY, inv9(p13q21)c[11] [12]
46, XX, der(2)t(2;6)(q31;q25), del(3)(q21~q23), der(6)(6pter->6q25::3q21~q23->3q29::16q23->16qter), 
der(16)t(2;16)(q31;q23)[19]
[12]
43-47, XX, +8, inv(9)(p12q12~q13)c [cp6]/47-48, XX, +der(1)del(1)(p?)del(1)(q?), +der(2)del(2)(p?), del(2)q?), inv(9)(p12q12~13)c 
[cp2]
[12]
46, XY, t(5;17)(p15, q22-23) present studyPage 2 of 8
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wised hybridisations using distal and proximal probes rel-
ative to the estimated breakpoints were selected until a
probe with split signal was observed. Based on this, new
BAC (Welcome Trust Sanger Institute, Cambridge, UK)
and fosmid probes (University of Santa Cruz California,
California, USA) covering the 5' and 3' parts of the rear-
ranged regions in CB13 were ordered and then labeled
with FITC or Cy3 d-UTPs using a random prime labelling
kit (Invitrogen, Breda, The Netherlands) according to the
manufacturer's instructions, with slight modifications
[18]. Hybridisation was performed on slides from met-
aphases of CB as previously described [18].
Array-Comparative Genomic Hybridisation (array-CGH)
The presence of extra copy number changes in CB13 was
explored by array-CGH using the 1 Mb large genomic
insert clone set distributed by the Wellcome Trust Sanger
Institute. DNA was isolated from snap-frozen tissue as
previously described [17]. Array printing, hybridisation,
and image-acquisition procedures were performed
according to a previous report [17].
Interphase FISH
Four micrometre-thick slides were prepared from snap-
frozen tissue from the fifteen cases previously mentioned.
Two split-apart probe sets at the CB13 breakpoint regions
were selected, set 1: RP11-422F20 and RP11-927L14
(Wellcome Trust Sanger Institute, Cambridge, United
Kingdom) on chromosome 5; and set 2: G248P87148D1
and G248P87022G6 on chromosome 17 (University of
Santa Cruz California, California, USA). Probes were
labelled by standard nick translation with biotin-16-dUTP
or digoxygenin-11-dUTP (Roche, Basel, Switzerland). The
hybridisation solution contained 50% formamide, 10%
dextran sulphate, 50 mM sodium phosphate, pH 7.0, 2
SCC, 3 ng/μl of each probe, and a 50-fold excess of human
Cot-1 DNA (BRL-Life Technologies, Rockville, MD).
Hybridisation and detection were performed as described
previously [19,20]. Slides were analysed by fluorescence
microscopy (microscope model DMRXA; Leica Microsys-
tems, Cambridge, UK). Image capture was performed by a
monochrome CCD camera (COHU, San Diego, CA)
attached to the fluorescence microscope and commercial
software (Q-FISH; Leica Imaging Systems). Confocal laser
scanning microscope (LSM510, Zeiss) in a multi-track set-
ting was used to combine images from phase contrast
with epifluorescence to recognise multinucleated giant
cells in CB13. Five bona fide multinucleated giant cells
were recognised and evaluated. All slides were first evalu-
ated by H&E staining and contained >70% neoplastic
cells. Two-hundred random nuclei were scored for detec-
tion of aberrations.
RT-PCR
Possible fusion products deriving from balanced translo-
cation in the index case were explored by RT-PCR. Exons
involved in eventual chimera formation were predicted
and a pool of primers were designed flanking the involved
exons; different combination of these primers are pre-
dicted to amplify both the normal product (used as a pos-
itive control for the reaction) as well as the eventual
fusion products. RNA was extracted and cDNA was syn-
thesised as previously described [5]. PCR reactions were
performed in a GeneAmp PCR system 9700 (Applied Bio-
systems, Foster City, CA) on 1 μL cDNA in a 25 μL reac-
tion containing 10 pmol of each primer, 1.5 μmol/L
MgCl2, 1 × PCR buffer II, and 0.5 unit AmpliTaq (Roche).
A reaction omitting the DNA template was run as a nega-
tive control. PCR-products were analysed by electrophore-
sis using a 1.5% agarose gel and ethidium bromide
staining for visualisation.
Immunohistochemistry
The levels and patterns of protein expression of steroid-5-
alpha-reductase, alpha polypeptide 1 (SRD5A1) and car-
bonic anhydrase-related protein (CA-RP X the protein
product of the CA10 gene), two genes respectively located
close to the re-arranged regions on chromosome 5 and 17,
were determined via immunohistochemistry. The former
gene is involved in sex steroid hormone metabolism.
Given the specific epidemiology of chondroblastoma
(i.e., more often affecting males and occurring in pre-
pubertal individuals), we consider it worthy to further
explore the sex steroid pathways. Subsequently, the level
of expression of oestrogen receptor alpha (ESR1), andro-
gen receptor (AR) and Cytochrome P450, family 19, sub-
family A, polypeptide 1 (CYP19A1) were also studied.
Immunohistochemistry was performed as previously
described [7] with slight modifications: Power Vision plus
(Immunologic, Duiven, the Netherlands) was used
instead of the SABC method, and visualisation was per-
formed using 3,3'-diaminobenzidine chromogen (DAB
plus, Dako SA, Glostrup, Denmark) (details are given in
Table 2). The slides were independently evaluated by two
pathologists (SR and PCWH). All the tumours were scored
using the sum of intensity of signal (possible range: 0 = no
expression; 1 = weak expression; 2 = moderate expression;
3 = strong expression) and the number of positive cells (%
tumour cells: 0 = 0%; 1 = 1-25%; 2 = 26-50%, 3 = 51-75%;
4 = 76-100%) as described previously [7]. The intracellu-
lar (nuclear, cytoplasmic, and membranous) and the
intra-tumoural (matrix rich areas or cellular areas) locali-
sation of immunoreactivity were noted. Particular atten-
tion was paid to multinucleated giant cells. Given the
heterogeneous location in the same tumours, the intensity
of signal and the distribution of staining were also evalu-
ated on a six-tiered scale: negative, weak focal, moderate
focal, weak diffuse, moderate diffuse, and strong diffuse.Page 3 of 8
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of expression of the studied molecules and age and gender
of the patients, including Fisher's exact test, Kruskal-Wal-
lis test and Mann-Whitney test as appropriate, were per-
formed with SPSS 11 software package.
Expression data meta-analysis
We explored significantly differential expression in chon-
droblastoma versus normal growth plate by interrogating
the expression array dataset we previously generated
[5,21]. Genes significantly differentially expressed were
identified with limma (Linear Model for Microarray Anal-
ysis) as previously described [5]. Furthermore, a global
test for the KEGG pathway androgen and oestrogen
metabolism http://cgap.nci.nih.gov/Pathways/Kegg/
hsa00150 was performed to identify eventual significant
altered expression levels of group of genes involved in this
pathway [22].
Results
COBRA-FISH based karyotyping of the index case (CB13)
showed 46, XY, t(5;17)(p15;q22-23)[20]/idemx2[5]/46,
XY[4] (Figure 1A). The presence of metaphase cells with
both rearranged and normal karyograms excluded the
possibility of a constitutional translocation. The balanced
nature of the rearrangement was supported by array-CGH
testing with no additional genomic copy number changes.
By FISH mapping, the breakpoint in 5p15 was demon-
strated to be proximal to the SRD5A1 gene region (Figure
1B). The breakpoint in 17q22-23 was proximal to the
CA10 gene region with a possible involvement of the gene
transcription regulatory element (19) (Figure 1B). RT-PCR
using potential chimera primer combinations was nega-
tive (data not shown).
Interphase FISH on tissue sections of the index case dem-
onstrated that the translocation only occurred in mono-
nuclear cells, while it was absent in multinucleated giant
cells (Figure 1B). Rearrangement of chromosome 5 and
17 was found only in the index case and not in the other
investigated chondroblastomas (Figure 1B). One case, CB
10, showed three unsplit signals for both the probes on
chromosome 5 as well as on chromosome 17, suggesting
either a possible trisomy of the two chromosomes or a tri-
ploidy in 2% of the cells (data not shown).
Diffuse expression of the SRD5A1 protein, as identified by
immunohistochemistry, was found in the index case as
well as in the other chondroblastomas (13/13 tested)
(Figure 1C). ESR1 (15/15) and CYP19A1 (15/15) showed
a similar pattern. AR showed intense positivity in scat-
tered cells in matrix-rich areas in 5 out of 15 cases (4 male
and 1 female) (Figure 1F) including the index case (Table
3). Absent CA-RP X protein expression, as identified by
immunohistochemistry, was found in CB13 (Figure 1D),
three cases showed low expression and the rest showed
weak to moderate intensity in most of the neoplastic cells
(Figure 1E). Moderate focal staining was found in multi-
nucleated giant cells for all the antibodies tested (Figure
1G). No significant correlation was found between level
of expression of the studied molecules and age and sex of
the patients.
The meta-analysis showed that only the gene BST2
(CDNA FLJ59809 complete cds, highly similar to Bone
marrow stromal antigen 2) (accession number:
NM_004335) had significantly higher expression in
growth plates versus chondroblastomas (adjusted p =
0.008). Global testing did not show any significant differ-
ences in the group of genes present on the expression
array that are involved in androgen and oestrogen metab-
olism.
Discussion
We report a novel balanced translocation t(5;17) in a
chondroblastoma case. No recurrent chromosomal
changes have ever previously been described in chondrob-
lastoma (Table 1) [11-15]. Even though involvement of
either chromosome 5 or 17 has been described in 5 out of
the 13 karyotypes reported thus far, no recurrent chromo-
some band involvement has been shown (Table 1) [11-
15]. FISH mapping identified breakpoints that occurred
Table 2: Details of the antibodies used for IHC.
Antigen Source Clone Staining Positive control Dilution Pre-incubation Antigen Retrieval
CA-RP X Experimental (22) MC Cytoplasm Nuclear Brain 1:50 Foetal calf serum 20 
min
None
SRD5A1 Novus Biological PC Cytoplasm Nuclear Prostate Carcinoma 1:100 None Citrate buffer/10 min 
mwo




AR Dako AR441 Nuclear Cervix 1:400 none TrisEDTA/10 min 
mwo
CYP19 Abcam PC Cytoplasm Placenta 1:300 Non-Fat Dry Milk 20 
min
Citrate buffer/10 min 
mwo
MC: monoclonal, PC: polyclonal, Mwo: microwave oven.Page 4 of 8
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on chromosome 5 and 17, respectively. We found no chi-
mera product by reverse transcriptase PCR. Since the FISH
mapping identified that the breakpoints occurred outside
the coding region, this translocation is hypothesised to
interfere with regulatory regions of the nearby genes. In
the region of the breakpoints, no other genes are reported.
CA-RP X (Carbonic anhydrase related protein X), the pro-
tein product of CA10, is a member of the CA family, and
SRD5A1 is involved in sex steroid metabolism. The CAs
(carbonic anhydrases) are monomeric zinc-metallo
enzymes that catalyse the reversible hydration of CO2.
These enzymes participate in a variety of biologic proc-
esses, including calcification and bone resorption. The
human CA gene family includes twelve active iso-enzymes
that exhibit characteristic catalytic activity (CA I-IV, VA,
VB, VI, VII, IX, XII, XIII and XIV) and three isoforms that
lack the CA activity due to the absence of one or more of
three zinc-binding His residues, which are critical for CA
catalytic activity. Thus, the latter have also been desig-
nated CA-related proteins VIII, X, and XI. Recent studies
have addressed the role of CAs in cancer; notably, CA IX
and CA XII have been reported to be over-expressed in sev-
eral carcinomas [23]. It has been hypothesised that these
transmembrane CA iso-enzymes may contribute to the
tumour micro-environment by maintaining the extracel-
lular acidic pH [24,25]. CA-RP VIII, which does not have
the catalytic CA activity as explained above, has been
shown to be predominantly expressed in colorectal cancer
cells at the tumour-invasion front [23]. However, the
mechanism driving this pattern of expression and its pos-
sible role in tumour invasion is largely unknown. CA-RP
X expression was previously reported to occur only in neu-
ral tissue [25,26]. The promoter region of the CA10 gene
has been intensively investigated; however, no defined
sequence has yet been identified [25]. Immunostaining
revealed that CA-RP X protein expression was absent in
the neoplastic cells of the index case and expressed at low
levels in three other cases. The lack of expression may
From identification of an index case to frequency of the re-arrangement and analysis of the candidate genesigure 1 (see previous page)
From identification of an index case to frequency of the re-arrangement and analysis of the candidate genes: A) 
COBRA-FISH molecular karyotypes on metaphases from CB13 shows translocation between the short arm of chromosome 5 
(white arrows) and the long arm of chromosome 17 (white arrows) (a schematic view of the rearrangement is given in the 
inset). B) The schematic view recapitulating the results of the FISH mapping (left) (chromosome 5 in the upper part and chro-
mosome 17 in the lower part) The probes that resulted translocated are shown in red, and the retained ones are shown in 
green. On the right (from top to bottom), interphase FISH shows splitting of the probes covering chromosomes 5 (top) and 17 
(bottom) breakpoint regions in the mononuclear cells of CB13, while no rearrangement was found in multinuclear giant cells 
(middle: confocal microscopy shows a giant cell with 2 nuclei with a normal paired red and green signal). C) Diffuse expression 
was found by immunohistochemistry for SRD5A1 (picture from CB13). Immunohistochemistry for carbonic anhydrase-related 
protein X is shown: absent signal in CB13 (D) and diffuse signal of moderate intensity in the other cases (E, CB11); heteroge-
neous staining was found in multinucleated giant cells. F) Scattered cells in matrix-rich areas were found to express AR (CB13). 
G) Heterogeneous staining was found in multinucleated giant cells for ESR1 (CB7) (magnification bar = 50 μm).
Table 3: Results of immunohistochemistry
Case number* Age sex Location SRD5A1 ESR1 AR CYP19 CA10
CB 2* 30 F Humerus 3 4 0 4 4
CB 3* 15 M Humerus 4 7 0 4 4
CB 4* 18 M Tibia 5 6 4 3 5
CB 5* 14 M Tibia 6 5 4 6 6
CB 6* 12 F Humerus 5 7 0 6 3
CB 7* 27 M os ischium 6 7 0 5 3
CB 8* 11 M Femur NA 5 0 0 4
CB 9* 12 M Femur 4 7 0 3 2
CB 10* 16 M Femur 6 3 0 5 2
CB 11* 12 M Tibia 3 3 2 3 3
CB 12* 17 F Humerus 6 3 0 3 5
CB 13* 18 M Humerus 6 7 4 3 0
CB 15* 14 F Humerus 6 7 3 3 3
CB 16* 18 F Humerus 6 7 0 2 2
CB 17* 15 M Humerus NA 7 0 4 4
Sum score is reported per each case per each antibody tested. M: male, F: female (age is reported in years) *The details of these cases were 
previously published (4). The index case is shown in bold. NA: not available; CB: ChondroblastomaPage 6 of 8
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by the translocation. Furthermore, it may indicate that
CA10 gene has an allele-specific expression pattern. In the
other three cases with low expression, another mecha-
nism diminishing the level of expression is hypothesised
to occur. In the remaining cases, a variable expression pat-
tern of the protein was observed. However, a pathogenic
role of other members of the CA family cannot be
excluded.
Sex steroids accelerate longitudinal growth in puberty [8].
Specifically, upon sexual maturation the level of circulat-
ing hormones is markedly increased. This is associated
with a dramatic increase in the length growth rate - the so-
called pubertal spurt. In both boys and girls, oestrogen is
a key determinant for the puberty-associated phenomena
related to longitudinal growth and bone quality [8,27].
Specifically in boys, most of the testosterone is converted
to oestrogen by CYP19; this enzyme is expressed in and
around the growth plate and regulates the local concentra-
tion of oestrogen [28]. However, a minor role might be
also played by androgens. Specifically, androgen receptors
are found in the growth plate [29]. SRD5A1 catalyses the
conversion of testosterone into the more potent andro-
gen, dihydrotestosterone. This latter hormone is able to
bind androgen receptors, which will translocate to the
nucleus thereby activating transcription of the down-
stream genes. Furthermore, dihydrotestosterone is a non-
aromatisable androgen (i.e., it cannot be converted to oes-
trogen by aromatase). Despite the above-mentioned role
of oestrogens in promoting the pubertal spurt, its action
on growth plate chondrocyte proliferation rate is not com-
pletely clear [8]. A low dosage of circulating oestrogens
may stimulate length growth through increased growth
plate chondrocyte proliferation [8]. On the other hand,
high circulating levels of oestrogens can induce growth
plate closure through accelerated bone replacement of
hypertrophic chondrocytes. Accordingly, ESR1 is mainly
found in growth plate hypertrophic chondrocytes [30].
Remarkably, the diffuse ESR1 expression chondroblast-
oma closely resembles the expression in hypertrophic
chondrocytes. We did not find a casual relationship
between the presence of the translocation and changes in
the levels of SRD5A1expression. However, diffuse expres-
sion of SRD5A1, ESR1 and CYP19 in all the chondroblas-
tomas tested, including the index case, was found. AR
showed a scattered expression in few cases, mainly in
males.
Taken together, our findings show a great similarity of lev-
els of expression, both at the protein level as well as at the
mRNA level, in sex steroid signalling-related molecules
between growth plates and chondroblastomas. This sup-
ports a possible role for this signalling in promoting chon-
droblastoma pathogenesis.
Finally, we observed intra-tumoural heterogeneity of the
staining pattern of multinucleated giant cells. We previ-
ously reported that a similar pattern of expression occurs
in multinucleated giant cells of chondroblastomas for
other molecules [7]. Some multinucleated giant cells
might be of syncytial origin or from impaired duplication
of neoplastic cells; however, our present findings lead us
to reject this latter hypothesis. In the index case, neoplas-
tic mononuclear cells displayed rearrangement of chro-
mosomes 5 and 17. In contrast, the nuclei from
multinucleated giant cells did not display rearrangements
in the specific chromosomal regions. Taken together,
these results favour a clonal origin of the mononuclear
cells of chondroblastoma and suggest that the multinucle-
ated giant cells within the lesions might be reactive.
Although we cannot exclude the multinucleated giant
cells have a different clonal origin, we consider it more
likely that the giant cells are osteoclast-like and recruited
through the RANK-ligand, which is present on the surface
of the chondroblast-like cells of chondroblastoma [31].
This is in parallel to the recruited nature of giant cells in
giant cell tumours of bone, which appear to be blood
born as shown by their immunophenotype [32].
Conclusion
In conclusion, we observed a case with a translocation at
t(5;17) with potential involvement of two candidate
genes. At the genome level, no disruption of the coding
sequences was observed; however, involvement of regula-
tory elements may have occurred. Although direct correla-
tion was observed only in the index case, a certain type of
molecular deficiency caused by the translocation might be
important for chondroblastoma pathogenesis. Diffuse
expression of SRD5A1 and sex steroid signalling-related
molecules confirms the role of this pathway in cartilagi-
nous tumours. Additionally, we determined that multinu-
cleated giant cells in chondroblastoma are most likely
reactive.
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